CHARLESTON, SC--(Marketwire - November 30, 2012) - Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCQB: RMCP) experienced its largest turnout ever at any trade show to date when the Company exhibited at the recent Medica Show in Dusseldorf, Germany.The Company conducted over 600 RevVac™ safety syringes demonstrations to more than 100 distributors, manufacturers, and health care professionals from 43 different countries during the four day conference and trade show. Interest was particularly high amongst representatives from European countries where the Directive to Prevent Sharps Injuries goes into effect on May 11, 2013.
The Company informed potential distributors that it expects to earn its CE Mark before May 2013. A CE Mark is required before the RevVac™ can be marketed and distributed within the European Union and other select countries throughout the Middle East.
Ron Wheet, Chief Executive Officer and Chairman of the Board of Revolutions Medical, explains, "There is a huge opportunity in Europe over the coming months with the RevVac™ safety syringe as the new European Union sharps prevention directive takes full effect. As we work towards the rollout of our 1ml, including insulin and tuberculin, 5ml and 10ml RevVac™ safety syringes, along with the completion of the CE Mark, we are confident that our product lines will be well positioned for growth in this market."
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its proprietary technologies and products include: the RevVac™ safety syringe, safety blood drawing device, the RevColor™, RevDisplay™, and Rev3D™ software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS) and prefilled vacuum auto-retraction safety syringes.
For additional information, please visit Revolutions Medical corporate website:
To be added to the Revolutions Medical investor email list, please email:
firstname.lastname@example.org with RMCP in the subject line.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.